A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patient (cT1-3 N1) who have - Owensboro Health

Skip to Content

A011202

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patient (cT1-3 N1) who have Positive Sentinel Lymph Node Disease a after Neoadjuvant Chemotherapy

Additional Information

Phase III

Purpose: To evaluate whether radiation to the un-disected axilla and regional lymph noed is inferior to axillary lymph node dissected axilla in terms of invasive breast cancer recurrence-free interval in patietn with postive Sentinel Lymph Node after complete of neo-adjuvant chemotherapy

 

Enrollment and Eligibility:

  • Age 18 years and older
  • Gender: Female
  • Disease: Breast Cancer (Stage T1-3, N1, M0)
  • Completed all planned chemo before surgery
  • Clinically negative axilla

ContactPerson:

  • Judy Strobel RN, BSN, OCN                                        
  • Clinical Research Specialist
  • Phone (270) 691-8094
  • Fax 270-688-3673
  • Email: Judith.Strobel @owensborohealth.org
IRB Protocol Number
12060831.0